CME Information

This activity is jointly provided by the University of Nebraska Medical Center and Bio Ascend.

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advance practitioners (NP/PA/PharmD), and other clinicians who treat patients with solid and hematologic cancers.

Learning Objectives

After participating in this activity, learners should be better able to:

  • Strive for and support other women in leadership positions in oncology
  • Foster team-based collaboration among women hematologists/oncologists, advanced practioners, and other healthcare professionals
  • Acquire insights that help further personal and professional growth
  • Evaluate evidence regarding the impact of gender imbalance on patient care

Joint Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been
planned and implemented by the University of Nebraska Medical Center and Bio Ascend LLC. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants who complete the educational activity and evaluation will receive an accredited continuing education credit certificate.


As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Julie Brahmer, MD, MSc
Consultant: Amgen, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Regeneron, Sanofi
Data and Safety Monitoring Board: Janssen
Grant/Research Support: AstraZeneca, Bristol Myers Squibb

Reshma Jagsi, MD, DPhil, FASTRO, FASCO
Stock Options/Advisory Board: Equity Quotient
Advisory Committee: National Institutes of Health, Greenwall Foundation, Doris Duke Charitable Foundation
Grants: National Institutes of Health, Doris Duke Foundation, Greenwall Foundation, Komen Foundation, Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium
Investigator-Initiate Study: Genentech
Expert Witness: Sherinian and Hasso, Dressman Benzinger LaVelle, and Kleinbard LLC

Pamela Kunz, MD
Advisory Boards: Amgen, Crinetics, Genentech, Hutchmed, Ipsen, ITM, Nateria
Research Funding to Institution: Novartis
Steering Committee: Novartis, Rayze Bio

Stephanie Lee, MD, MPH
Consulting Fees: Equillium, Kadmon, Mallinckrodt
Research Funding: Amgen, AstraZeneca, Incyte Corporation, Kadmon, Novartis, Pfizer, Syndax, Takeda
Drug Supply: Janssen
Clinical Trial Steering Committee: Incyte Corporation

Edith Mitchell, MD, FACP, FCPP, FRCP
Speakers Bureau: Amgen, Genentech, Ipsen, Taiho
Advisory Board: Amgen, Caris, Bristol Myers Squibb, Genentech, Merck, Novartis
Research Funding to Institution: Genentech, Sanofi

Debra Patt, MD, PhD, MBA, FASTRO
Educational Consultant: Pfizer

Lori Pierce, MD, FASTRO, FASCO
Royalties: UpToDate

Susan Scott, MD
Advisory Board: Roche/Genentech

Nina Shah, MD
Research Funding: Bluebird Bio, Celgene/BMS, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, Teneobio
Advisory Role: Allogene, Amgen, CareDx, CSL Behring, GSK, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, Sanofi
Employment, Stock:
AstraZeneca (as of 7/2022)

Rachna Shroff, MD, MS
Advisory Board: AstraZeneca, Boehringer Ingelheim Pharma, CAMI, Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier/Agios, Taiho, Zymeworks
Consultant: SYROS
DMC: Merck
Research Funding: Bayer, Bristol Myers Squibb, Exelixis, IMV, Inc, Loxo, Novocure, NUCANA, Pieris, QED Therapeutics, Rafael Pharmaceuticals, Seagen, Taiho

Susan W. Sweeney, MPH
Employed by Amgen

Margaret A. Tempero, MD
Data Safety Monitoring Committee: Astellas Pharma Global Development Inc.
Advisory Board: BeiGene, BioSapiens, BlueStar, IQVIA Ltd., Seagen, Inc., Steba Biotech
Consultant: B2ACT Therapeutics Genex, Debiopharm, IPSEN Biopharma, Inc., Incyte, Institut Jules Bordet, Insmed Incorporated, Novartis Pharmaceuticals

Julie M. Vose, MD, MBA
Research/Consultant: AbbVie, Astra Zeneca, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Johnson & Johnson, Lilly, MEI Pharma, Pharmacyclics

The following faculty have no relevant financial relationships to disclose:

Sibel Blau, MD
Nancy E. Davidson, MD
Stephanie Barron Hall, MA
LeeAnn Mallorie, MAPP, MSC
Laleh Melstrom, MD, MS
Catherine Tinsley, PhD
Elizabeth Travis, PhD, FASTRO

Planning Committee
The following planning committee members have no relevant financial relationships to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Aimee Harwood; Allison Meier; Kraig Steubing

Advisory Committee
The following Advisory Committee members have no relevant financial relationships to disclose:
Linda Bosserman, MD, FACP, FASCO
Narjust Florez, MD
Jarushka Naidoo, MBBCH, MD
Sapna Patel, MD
Elizabeth Plimack, MD, MS
Ana Velazquez Manana, MD
Shannon Westin, MD, MPH, FACOG

Request for Credit In order to obtain your CME certificate, please follow the steps below within 30 days of the conclusion of the conference:

  1. Complete the program evaluation. A CME request form will pop up once you submit the evaluation
  2. Complete the CME request form and email to
  3. Your certificate will be emailed to you within 30 days